Strategies for gene therapy.
The use of retroviral-mediated gene transfer to introduce a DNA label into T cells (TIL) being used in the immunotherapy of patients with malignant melanoma finally opened the door to the clinical application of gene therapy for a wide variety of inherited and acquired diseases. The gene therapy trial for ADA deficiency SCID has demonstrated that long term stable expression of exogenous genes can be achieved in human T lymphocytes using retroviral vectors for ex vivo treatment and that significant immune reconstitution can be achieved in these patients following periodic infusions with ADA gene-corrected autologous T cells. Newer clinical applications include the insertion of genes into CD34 enriched stem cell populations, the testing of autologous tumor vaccines employing cytokine gene-modified tumor cells and the direct transfer of the herpes thymidine kinase gene into brain tumors in situ in order to render those tumors sensitive to treatment with the ordinarily non-cytotoxic drug ganciclovir.
Blaese
R M
RM
Cellular Immunology Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Mullen
C A
CA
Ramsey
W J
WJ
D000163:Acquired Immunodeficiency Syndrome / Q000235:genetics / Q000628:therapy*; D016026:Bone Marrow Transplantation; D015774:Ganciclovir; D018014:Gene Transfer Techniques; D030342:Genetic Diseases, Inborn / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics
D015774:Ganciclovir